抗肿瘤药物递送系统研究进展

doi:10.3760/cma.j.cn371439-20240701-00027

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (3): 176-179.doi: 10.3760/cma.j.cn371439-20240701-00027

抗肿瘤药物递送系统研究进展

张百红¹, 岳红云²()

¹中国人民解放军联勤保障部队第九四〇医院肿瘤科，兰州 730050
²中国人民解放军联勤保障部队第九四〇医院眼科，兰州 730050

收稿日期:2024-07-01 修回日期:2024-07-20 出版日期:2025-03-08 发布日期:2025-04-02
通讯作者: 岳红云，Email：yhyophthalmologist@163.com
基金资助:
甘肃省自然科学基金(22JR5RA007);联勤保障部队第九四〇医院课题(2021yxky052)

Advances in anticancer drug delivery systems

Zhang Baihong¹, Yue Hongyun²()

¹Department of Oncology，940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army，Lanzhou 730050，China
²Department of Ophthalmology，940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army，Lanzhou 730050，China

Received:2024-07-01 Revised:2024-07-20 Online:2025-03-08 Published:2025-04-02
Contact: Yue Hongyun，Email：yhyophthalmologist@163.com
Supported by:
Natural Science Foundation of Gansu Province of China(22JR5RA007);Research Subject of 940th Hospital of Joint Logistics Support Force(2021yxky052)

摘要/Abstract

摘要：

药物递送系统（DDS）可以降低抗肿瘤药物的脱靶效应。抗肿瘤药物DDS的载体主要有纳米微粒、小分子、核酸、多肽和抗体以及细胞，它们通过连接器携载抗肿瘤药物，将药物递送至特异的肿瘤组织和细胞。DDS将推动肿瘤精准医学的发展。

关键词: 肿瘤, 治疗, 药物递送系统

Abstract:

Drug delivery system （DDS） holds promise in reducing off-target effects of antitumor drugs. The carriers of antitumor drug DDS mainly include nanoparticles，small molecules，nucleic acids，peptides，antibodies and cells，which carry antitumor drugs through linker to deliver the drugs to specific tumor tissues and cells. DDS will propel progress in the field of cancer precision medicine.

Key words: Neoplasms, Therapy, Drug delivery systems

张百红, 岳红云. 抗肿瘤药物递送系统研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 176-179.

Zhang Baihong, Yue Hongyun. Advances in anticancer drug delivery systems[J]. Journal of International Oncology, 2025, 52(3): 176-179.

参考文献 33

[1]	Zhao Z, Ukidve A, Kim J, et al. Targeting strategies for tissue-specific drug delivery[J]. Cell, 2020, 181(1): 151-167. DOI: 10.1016/j.cell.2020.02.001. pmid: 32243788
[2]	Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies[J]. Nat Biomed Eng, 2021, 5(9): 951-967. DOI: 10.1038/s41551-021-00698-w. pmid: 33795852
[3]	Nelson BJ, Pané S. Delivering drugs with microrobots[J]. Science, 2023, 382(6675): 1120-1122. DOI: 10.1126/science.adh3073. pmid: 38060660
[4]	Huayamares SG, Loughrey D, Kim H, et al. Nucleic acid-based drugs for patients with solid tumours[J]. Nat Rev Clin Oncol, 2024, 21(6): 407-427. DOI: 10.1038/s41571-024-00883-1. pmid: 38589512
[5]	Jiang Y, Lyu Z, Ralahy B, et al. Dendrimer nanosystems for adaptive tumor-assisted drug delivery via extracellular vesicle hijacking[J]. Proc Natl Acad Sci U S A, 2023, 120(7): e2215308120. DOI: 10.1073/pnas.2215308120.
[6]	Zhang Y, Liu F, Zhang Y, et al. Self-powered, light-controlled, bioresorbable platforms for programmed drug delivery[J]. Proc Natl Acad Sci U S A, 2023, 120(11): e2217734120. DOI: 10.1073/pnas.2217734120.
[7]	Li F, Yang F, Guan C, et al. Preparation and cytotoxicity evaluation of folic acid-modified YF8-OA self-assembled lipid prodrug nanoparticles[J]. Pharm Dev Technol, 2023, 28(5): 452-459. DOI: 10.1080/10837450.2023.2206487.
[8]	Abdul Rahman A, Mohd Isa IL, Tofail SAM, et al. Modification of living diatom, Thalassiosira weissflogii, with a calcium precursor through a calcium uptake mechanism: a next generation biomaterial for advanced delivery systems[J]. ACS Appl Bio Mater, 2024, 7(6): 4102-4115. DOI: 10.1021/acsabm.4c00431.
[9]	Peng X, Tang S, Tang D, et al. Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy[J]. Sci Adv, 2023, 9(23): eadh1736. DOI: 10.1126/sciadv.adh1736.
[10]	Gwisai T, Mirkhani N, Christiansen MG, et al. Magnetic torque-driven living microrobots for increased tumor infiltration[J]. Sci Robot, 2022, 7(71): eabo0665. DOI: 10.1126/scirobotics.abo0665.
[11]	Horns F, Martinez JA, Fan C, et al. Engineering RNA export for measurement and manipulation of living cells[J]. Cell, 2023, 186(17): 3642-3658.e32. DOI: 10.1016/j.cell.2023.06.013. pmid: 37437570
[12]	Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond[J]. Nat Rev Drug Discov, 2023, 22(6): 476-495. DOI: 10.1038/s41573-023-00671-z.
[13]	Kim J, Lee S, Kim Y, et al. In situ self-assembly for cancer therapy and imaging[J]. Nat Rev Mater, 2023, 8(11): 710-725. DOI: 10.1038/s41578-023-00589-3.
[14]	Wei L, Li G, Lu T, et al. Functionalized graphene oxide as drug delivery systems for platinum anticancer drugs[J]. J Pharm Sci, 2021, 110(11): 3631-3638. DOI: 10.1016/j.xphs.2021.07.009.
[15]	Raimondo TM, Reed K, Shi D, et al. Delivering the next generation of cancer immunotherapies with RNA[J]. Cell, 2023, 186(8): 1535-1540. DOI: 10.1016/j.cell.2023.02.031. pmid: 37059063
[16]	Tsuchida CA, Wasko KM, Hamilton JR, et al. Targeted nonviral delivery of genome editors in vivo[J]. Proc Natl Acad Sci U S A, 2024, 121(11): e2307796121. DOI: 10.1073/pnas.2307796121.
[17]	Berillo D, Yeskendir A, Zharkinbekov Z, et al. Peptide-based drug delivery systems[J]. Medicina (Kaunas), 2021, 57(11): 1209. DOI: 10.3390/medicina57111209.
[18]	Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182. DOI: 10.3322/caac.21705.
[19]	Mair MJ, Bartsch R, Le Rhun E, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours[J]. Nat Rev Clin Oncol, 2023, 20(6): 372-389. DOI: 10.1038/s41571-023-00756-z. pmid: 37085569
[20]	Alapan Y, Yasa O, Schauer O, et al. Soft erythrocyte-based bacterial microswimmers for cargo delivery[J]. Sci Robot, 2018, 3(17): eaar4423. DOI: 10.1126/scirobotics.aar4423.
[21]	Tang S, Zhang F, Gong H, et al. Enzyme-powered Janus platelet cell robots for active and targeted drug delivery[J]. Sci Robot, 2020, 5(43): eaba6137. DOI: 10.1126/scirobotics.aba6137.
[22]	Zhang H, Li Z, Gao C, et al. Dual-responsive biohybrid neutrobots for active target delivery[J]. Sci Robot, 2021, 6(52): eaaz9519. DOI: 10.1126/scirobotics.aaz9519.
[23]	Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug[J]. Nature, 2023, 619(7971): 707-715. DOI: 10.1038/s41586-023-06243-w.
[24]	Baulu E, Gardet C, Chuvin N, et al. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives[J]. Sci Adv, 2023, 9(7): eadf3700. DOI: 10.1126/sciadv.adf3700.
[25]	Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles[J]. Nat Rev Clin Oncol, 2023, 20(1): 33-48. DOI: 10.1038/s41571-022-00699-x.
[26]	Alsaiari SK, Qutub SS, Sun S, et al. Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy[J]. Sci Adv, 2021, 7(4): eabe7174. DOI: 10.1126/sciadv.abe7174.
[27]	Akolpoglu MB, Alapan Y, Dogan NO, et al. Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery[J]. Sci Adv, 2022, 8(28): eabo6163. DOI: 10.1126/sciadv.abo6163.
[28]	Banskota S, Raguram A, Suh S, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins[J]. Cell, 2022, 185(2): 250-265.e16. DOI: 10.1016/j.cell.2021.12.021. pmid: 35021064
[29]	Zhang F, Li Z, Duan Y, et al. Gastrointestinal tract drug delivery using algae motors embedded in a degradable capsule[J]. Sci Robot, 2022, 7(70): eabo4160. DOI: 10.1126/scirobotics.abo4160.
[30]	Berger S, Lächelt U, Wagner E. Dynamic carriers for therapeutic RNA delivery[J]. Proc Natl Acad Sci U S A, 2024, 121(11): e2307799120. DOI: 10.1073/pnas.2307799120.
[31]	Madigan V, Zhang F, Dahlman JE. Drug delivery systems for CRISPR-based genome editors[J]. Nat Rev Drug Discov, 2023, 22(11): 875-894. DOI: 10.1038/s41573-023-00762-x. pmid: 37723222
[32]	Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents[J]. Cell, 2022, 185(15): 2806-2827. DOI: 10.1016/j.cell.2022.03.045. pmid: 35798006
[33]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. DOI: 10.3760/cma.j.cn371439-20240318-00061.

抗肿瘤药物递送系统研究进展

Advances in anticancer drug delivery systems

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王逸, 王强力, 张甲, 杨懿瑾, 王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[2]	韩涛, 贾沛沛, 鲁静. iRhom1、iRhom2、TNF-α水平对宫颈癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2025, 52(3): 158-162.
[3]	李志远, 贾秀红. 铜死亡在肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 163-168.
[4]	欧阳苏瑞, 孙梦颖, 唐桩, 李进, 何敬东. 瘤内免疫注射药物及药物递送载体的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 169-175.
[5]	王智颖, 盛立军. 外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.
[6]	王菲菲, 赵守香, 李颖, 王涛, 郭琴, 田胜南, 蔡晓珊. 气球状细胞黑色素瘤肝转移1例[J]. 国际肿瘤学杂志, 2025, 52(3): 190-192.
[7]	邢辉, 谭莹, 王秀珍, 李瑞, 刘霞. NLR、TNF-α水平对巨块型肝癌患者TACE联合微波消融治疗效果的预测分析[J]. 国际肿瘤学杂志, 2025, 52(2): 101-106.
[8]	王熙博, 田宝文, 陈士巧. Breg细胞在肿瘤免疫逃逸中的机制及相关治疗靶点[J]. 国际肿瘤学杂志, 2025, 52(2): 107-112.
[9]	叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.
[10]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[11]	. 胃癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(2): 65-66.
[12]	中国临床肿瘤学会肿瘤支持与康复治疗专家委员会, 癌因性厌食诊疗中国专家共识工作组. 癌因性厌食诊疗中国专家共识[J]. 国际肿瘤学杂志, 2025, 52(2): 67-78.
[13]	王智宝, 李广现, 张昕昕, 崔伟, 张微. MRI联合血清lncRNA KCNQ1OT1、miR-204-5p对乳腺癌腋窝淋巴结转移的预测价值[J]. 国际肿瘤学杂志, 2025, 52(2): 89-93.
[14]	姬海涛, 王延峰, 刘永成, 郝楠. 基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[15]	. 食管癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(1): 1-2.